Detalhe da pesquisa
1.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916367
2.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923550
3.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
4.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
5.
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood
; 119(1): 55-63, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22001391
6.
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer.
BMC Cancer
; 9: 374, 2009 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843336
7.
KRAS mutations predict response to EGFR inhibitors.
Curr Opin Pharmacol
; 8(4): 413-8, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18619559
8.
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Clin Cancer Res
; 13(7): 2254-60, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17404110
9.
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
Cancer Res
; 66(15): 7466-72, 2006 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16885343
10.
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.
Cell Rep
; 23(3): 918-929, 2018 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669295
11.
Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.
Clin Cancer Res
; 24(12): 2944-2950, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29535126
12.
Genomic loss of heterozygosity and survival in the REAL3 trial.
Oncotarget
; 9(94): 36654-36665, 2018 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30613349
13.
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
JCO Precis Oncol
; 2: 1-13, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135111
14.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 7(9): 984-998, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28588062
15.
RNA-mediated gene silencing in non-pathogenic and pathogenic fungi.
Curr Opin Microbiol
; 5(3): 323-9, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12057689
16.
Dominant genetic screen for cofactors that enhance antisense RNA-mediated gene silencing in fission yeast.
Nucleic Acids Res
; 30(11): 2546-54, 2002 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12034844
17.
Double-stranded RNA-mediated gene silencing in fission yeast.
Nucleic Acids Res
; 31(15): 4481-9, 2003 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12888508
18.
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
J Thorac Oncol
; 11(10): 1690-700, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27468937
19.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Clin Cancer Res
; 22(10): 2386-95, 2016 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26747242
20.
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Cancer Discov
; 5(7): 713-22, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25934077